2-Hydroxyglutarate in onco-pathway: a metabolic driver of proto-oncogene activation
-
By
-
Masthan Thamim
-
Debdas Dhabal
-
M. M. Balamurali
-
Krishnan Thirumoorthy
-
April 30, 2026
-
Clinical Scorecard: The Role of 2-Hydroxyglutarate in Cancer Pathways: A Metabolic Influencer of Proto-Oncogene Activation
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Cancer patients with specific types of cancer associated with 2HG, such as gliomas and acute myeloid leukemia. |
| Care Setting | |
Key Highlights
- 2-Hydroxyglutarate (2HG) acts as an oncometabolite influencing tumor progression and therapy resistance, particularly in gliomas.
- D-2HG and L-2HG inhibit α-KG-dependent dioxygenases, disrupting epigenetic regulation and contributing to therapy resistance.
- Metabolic alterations in cancer cells lead to uncontrolled proliferation and increased resistance to therapies.
Guideline-Based Recommendations
Diagnosis
Management
- Target metabolic pathways influenced by 2HG, such as the TCA cycle and histone demethylation, to disrupt cancer signaling.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Therapeutic strategies may include targeting metabolic pathways associated with 2HG, such as IDH inhibitors.
Clinical Best Practices
- Integrate metabolic profiling in cancer diagnosis and treatment planning based on current clinical trials and guidelines.
References
